ACUT (Accustem Sciences) EV-to-EBIT : -10.22 (As of Jul. 17, 2025)

View and export this data going back to 2022. Start your Free Trial

What is Accustem Sciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Accustem Sciences's Enterprise Value is $14.49 Mil. Accustem Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.42 Mil. Therefore, Accustem Sciences's EV-to-EBIT for today is -10.22.

The historical rank and industry rank for Accustem Sciences's EV-to-EBIT or its related term are showing as below:

ACUT' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.22 Med: 0 Max: 0
Current: -10.22

ACUT's EV-to-EBIT is ranked worse than
100% of 441 companies
in the Biotechnology industry
Industry Median: 11.31 vs ACUT: -10.22

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Accustem Sciences's Enterprise Value for the quarter that ended in Mar. 2025 was $8.32 Mil. Accustem Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.42 Mil. Accustem Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -17.04%.

Accustem Sciences EV-to-EBIT Historical Data

The historical data trend for Accustem Sciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accustem Sciences EV-to-EBIT Chart

Accustem Sciences Annual Data

Trend

Dec22

Dec23

Dec24

EV-to-EBIT

-3.92

-3.48

-3.62

Accustem Sciences Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBIT	Get a 7-Day Free Trial								-2.27	-2.44	-3.16	-3.62	-5.87

Competitive Comparison of Accustem Sciences's EV-to-EBIT

For the Biotechnology subindustry, Accustem Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accustem Sciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Accustem Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Accustem Sciences's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Accustem Sciences EV-to-EBIT Calculation

Accustem Sciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	14.485	/	-1.418
	=	-10.22

Accustem Sciences's current Enterprise Value is $14.49 Mil.
Accustem Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.42 Mil.

Accustem Sciences (OTCPK:ACUT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Accustem Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 )	=	EBIT	/	Enterprise Value (Q: Mar. 2025 )
	=	-1.418	/	8.32144
	=	-17.04 %

Accustem Sciences's Enterprise Value for the quarter that ended in Mar. 2025 was $8.32 Mil.
Accustem Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.42 Mil.

Accustem Sciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Accustem Sciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Accustem Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Accustem Sciences Inc (OTCPK:ACUT) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

5 Penn Plaza, Suite 1954, Floor 19th, New York, NY, USA, 10001

Website

https://www.accustem.com

Accustem Sciences Inc is a life sciences company that focuses on enhancing cancer patient outcomes through diagnostic, pharmaceutical, and medical device products. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services. Operations span New York, NY, and London, UK.